Conferences & Events

GAIN Mayo Clinic

GAIN: EnGAging an Interdisciplinary Team for NSCLC Diagnosis, Personalized Assessment, and Treatment

REGIONAL SUMMIT

In collaboration with Mayo Clinic

Friday, September 18, 2015

8:30 AM-3:15 PM

Renaissance Phoenix Downtown Hotel
50 East Adams Street
Phoenix, Arizona

Note - There is no cost to participate in this activity.
 
REGISTER NOW
 
Take part in this important educational initiative, and you will have the opportunity to earn CME credit and gain access to performance improvement activities developed by CHEST, the American Society for Clinical Pathology, the National Comprehensive Cancer Network® (NCCN®), IASLC and The France Foundation.

Summit Chair

Helen J. Ross, MD
Associate Professor of Medicine
Mayo Clinic

Summit Steering Committee

Eric S. Edell, MD, FCCP (Co-chair)
Mayo Clinic

Septimiu Murgu, MD, FCCP (Co-chair)
The University of Chicago Medicine

Mari Mino-Kenudson, MD
Harvard Medical School

David S. Ettinger, MD
The Sidney Kimmel Comprehensive Cancer Center at
Johns Hopkins

Suresh S. Ramalingam, MD
Emory University School of Medicine
Winship Cancer Institute

What’s Unique About This Program?

This one-day curriculum on lung cancer education incorporates the following learner-centric elements:

  1. Hands-on experience including mediastinal anatomy pertinent to lung cancer staging, EBUS-TBNA specimen acquisition, smear preparation, specimen handling and pathology analysis, histo- and cytomorphologic diagnosis, immunotherapy and molecular markers relevant to NSCLC
  2. Team approach to lung cancer diagnosis and management. This is performed through problem-based learning “Practical Approach” exercises, which provide learners with a framework for “thinking-through” a patient-based clinical scenario. This simulates a multispecialty team approach to personalized care of patients suffering from lung cancer
  3. Interactive, audience participation “tumor board” session to encourage honest, individual responses. Group responses allow faculty to focus on the group as well as each individual’s learning needs and apply learner-centric teaching strategies

Due to the nature of this learner-centric education, capacity is limited to 40 participants.

Summit Overview:

  • Tumor Board Presentation/Discussion of Cases
  • Breakout 1: Mediastinal Anatomy
  • Breakout 2: Sample Acquisition, Preparation, Interpretation
  • Breakout 3: Pathology Analysis
  • Breakout 4: Treatment
  • Problem-Based Learning Sessions

 
Through case-based discussions and interactive simulations, this interdisciplinary summit will seek to address specific unmet needs and clinical gaps in the care of patients with locally advanced and metastatic non-small cell lung cancer (NSCLC). The goal is to advance the knowledge, competence, and performance of a team of interdisciplinary specialists who are currently responsible for appropriate staging, mediastinal lymph node assessment, tissue acquisition, biomarker analysis and immunotherapy in patients with NSCLC.
 
At the conclusion of this activity, you should be able to:

  • Describe and demonstrate knowledge required to obtain an adequate tissue sample for NSCLC diagnosis and classification
  • Identify current biomarkers utilized to categorize molecular and histologic features of NSCLC and their relevant applications for diagnosis, monitoring, and personalized care
  • Identify a NSCLC coordinated care plan among interdisciplinary colleagues and develop a plan for implementation
Accreditation Information

Physicians
The American College of Chest Physicians (CHEST) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CHEST designates this live activity for a maximum of 5.25 AMA PRA Category 1 Credits™. Individuals should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Provider-approved by the California Board of Registered Nursing, Provider Number 16433, for 5.25 contact hours.

In accordance with the Physician Payment Sunshine Act, manufacturers of pharmaceutical drugs and devices, as well as group purchasing organizations, must report payments or transfers of value (such as meals, honoraria, or travel reimbursements) made to US physicians.

Because meals are provided for this course, some manufacturers who provided support may require the reporting of information about physicians attending this course. If a manufacturer requests information, CHEST will provide your name, business address, specialty, NPI and license number, as well as the estimated individual value of your meals.

Please consider the above information prior to registering for this course.

Presented through an educational collaboration by CHEST, ASCP, the National Comprehensive Cancer Network® (NCCN®), IASLC, and The France Foundation.

We gratefully acknowledge the following for their financial support of GAIN 3.0:

  • Bristol-Myers Squibb
  • Genentech/Astellas
  • Merck
  • Lilly USA, LLC